FBXW7 mutation in CRC leads to tumor cell proliferation, increases resistance to paclitaxel, 5-fluorouracil and oxaliplatin, as well as becomes sensitive to mTOR inhibitors (35–37). Here, MTOR is linked to neoplasm.